Detection of Tumor DNA in Blood Samples From Cancer Patients
NCT ID: NCT02288754
Last Updated: 2019-08-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
500 participants
OBSERVATIONAL
2014-12-31
2020-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Detection of Tumor DNA in Blood Samples From Patients With Early Stage Cancer and "Healthy Controls"
NCT03071809
Collecting and Storing Blood Samples From Patients With Cancer
NCT00900120
Targeted Genomic Analysis of Blood and Tissue Samples From Patients With Cancer
NCT02688517
Genetic Investigation of Cancer Predisposition
NCT04620278
Clinical Utility of Circulating Tumor DNA in Gastro-Esophageal Cancer
NCT04576858
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Stage II or III curative surgery (closed to accrual)
Patients with stage II or III solid tumors undergoing curative intend surgery enrolled before surgery.
Blood test
No intervention except to collect blood for diagnostic test development
Stage II or III neoadjuvant therapy cohort (closed to accrual)
Patients with stage II or III solid tumors undergoing neoadjuvant therapy followed by curative intend surgery enrolled before neoadjuvant therapy.
Blood test
No intervention except to collect blood for diagnostic test development
Metastatic disease
Patients with advanced, recurrent and/or metastatic disease requiring systemic therapy with chemotherapy, targeted therapy, immunotherapy or a combination of any before initiation of any therapy or a new line of therapy following documentation of disease progression on prior therapy.
Blood test
No intervention except to collect blood for diagnostic test development
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Blood test
No intervention except to collect blood for diagnostic test development
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Have metastatic disease with from a solid tumor (e.g. breast, lung, colon, pancreas, ovary, prostate...) or stage II or III solid tumors undergoing curative surgery or neoadjuvant therapy followed by surgery
* Starting treatment or a new line of treatment
* Able to understand and grant informed consent
* Able to have their blood drawn
Exclusion Criteria
* Has a hematological malignancy, i.e. myeloma, lymphoma, MDS, leukemia
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Lexent Bio, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Haluk Tezcan, MD
Role: PRINCIPAL_INVESTIGATOR
Lexent Bio
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Cancer Care Associates
Torrance, California, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
David Chan, MD
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
LB1985106
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.